



08-3001

C10 Rec'd PCT/PTA 29 AUG 2001

146.1339

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
FRANCIS PETIT et al
Serial No.: 554,772
Filed: May 16, 2000
For: USE OF...ATHEROSCLEROSIS

: E. Ghashghaee

: Group: 1656

RECEIVED

NOV 08 2001

TECH CENTER 1600/2900

600 Third Avenue
New York N.Y. 10016
August 29, 2001


SECOND REQUEST FOR CORRECTED FILING RECEIPT

Asst. Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants are returning herewith the corrected filing receipt for the above application and ask that the Patent Office issue a new filing receipt with a corrected title. The title should read USE OF KETOLIDES FOR PREVENTING ARTERIAL THROMBOTIC COMPLICATIONS RELATED TO ATHEROSCLEROSIS and the title in the corrected filing receipt, the Patent Office deleted the term "ARTERIAL" was deleted.

Respectfully submitted,
Bierman, Muserlian and Lucas


Charles A. Muserlian #19,683
Attorney for Applicants
Tel.# (212) 661-8000

CAM:ds
Enclosures

EL 7440239054S
Aug 29, 2001

RECEIVED
AUG 29 2001
TECH CENTER 1600/2900
1.13
Remarks: In compliance with the provisions of the Patent and Trademark Office, the title of the application has been corrected to read: USE OF KETOLIDES FOR PREVENTING ARTERIAL THROMBOTIC COMPLICATIONS RELATED TO ATHEROSCLEROSIS.

Aug 29, 2001
D. Halconer



RECEIVED

Page 1 of 4


NOV 08 2001

TECH CENTER 1800/2900

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP PART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/554,772	05/16/2000	2899	970	146.1339		4	1

CHARLES A MUSERLIAN
BIERMAN MUSERLIAN & LUCAS
600 THIRD AVENUE
NEW YORK, NY 10016



CONFIRMATION NO. 6484

CORRECTED FILING RECEIPT



OC000000006470687

BIERMAN, MUSERLIAN AND LUCAS

Date Mailed: 08/24/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

FRANCIS PETIT, COLOMBES, FRANCE;
FRANCOISE VACHERON, PARIS, FRANCE;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/FR98/02436 11/16/1998

Foreign Applications

If Required, Foreign Filing License Granted 06/21/2000

Projected Publication Date: N/A

Non-Publication Request: No

Early Publication Request: No

Title

USE OF KETOLIDES FOR PREVENTING THROMBOTIC COMPLICATIONS RELATED TO
ATHEROSCLEROSIS

Preliminary Class

XXX

Data entry by : BROWN, MICHAEL

Team : 1600

Date: 08/24/2001



RECEIVED

NOV 08 2001

TECH CENTER 1600/2900

RECEIVED

NOV 08 2001

TECH CENTER 1600/2900

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231